Member Info for silverhorse

Poor price - u ok huld?

Skillington describes the challenge of developing an oral vaccine that is able to survive for enough time inside the body to take effect, and says there are "lots of benefits for oral vaccines over injections."

Am expecting grant funding for POLB -003 US ! I always liked the oral vaccine another winner 10p is crazy cheap - you can sell millions 9.5p its going up alot more this week - goodluck all

Focus on the company not the share price - it will settle around 11p this week before all the very positive news flow -

2023 will be the year

My bet is a takeover - not sure what price would be acceptable need to wait for all the news flow lots coming 2023 star AIM stock - 70p sounds right !

We look forward to updating the market as POLB 002 progresses, with the ultimate aim of partnering it with pharma / biotech.

Benefits of Oral Vaccines =Easier distribution & administration Overcomes needle phobia = Preliminary data has shown that this platform may enhance the uptake of antigens to specific cells. This technology may be used to protect and deliver a wide range of fragile molecules such as proteins, peptides, DNA and RNA and activate a specific immune response.

POLB 003 – Melioidosis Vaccine Candidate = Grant funding US =poolbeg is performing diligence on additional bacterial vaccine candidates that the UCD team has identified with a view of potentially in-licencing for further development.

POLB 001 = LPS human challenge trial commenced in July 2022 with initial early human efficacy data expected by year end 2022

The final stage of the research plan will utilise OneThree’s proprietary ATLANTIS AI platform to identify the drugs that are most likely to be efficacious against the identified disease targets with clean safety profiles in RSV patients. Selection of drugs is traditionally a long and extensive process, however, by using an existing AI model this process can be completed in weeks. Results of this stage are expected before year end 2022.

CytoReason and Pfizer sign $110M collaboration deal! = Poolbeg signed a deal with CytoReason, a leading AI company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg’s influenza disease progression data derived from human challenge study samples.

moniman - Agree , i did say something not adding up there

No chance now - i did sell a few weeks back but i decided to buy all back X3 - holding firm. unbelievable upside!!!!!!!!!!!!!

Hi cashintime -So certain this is a serious winner 14p is chicken feed when all is out - best hold for the big move up up to 70p would not rule that out

max111 - we need this over 1p

moinman - This is going up - lots of far size buys 7p last few weeks - 14p weeks ahead takeover likely 60p nice!

FS out soon ?

Huld - Did you get shares 0.35 ?

FY 2022 results little more then 2021 likely very good but short tern sell wait for 2023 results much better u agree PC ?